Good news. I would presume the extra 22 enrollees is based on percentage of successful completions they are experiencing thus far (with a little bit of buffer). 15% elimination/dropout seems quite reasonable. Can we presume it's skewed toward placebo recipients?
Interim readout still on schedule! Oh no, how can that be if the drops are a complete failure and participants are fleeing the trial!
With the inclusion of actual enrollment numbers the company did a great job of responding to the bobastic and unfounded assertions being made by the short sellers and those who seem to think short term stock price is ultimate long term truth.